Greenwich Lifesciences, INC

Greenwich LifeSciences, Inc. announced the successful election of all five director nominees and the ratification of MaloneBailey LLP as its independent auditor at its Annual Meeting of Stockholders.

Greenwich LifeSciences, Inc. has dismissed RBSM LLP and engaged MaloneBailey LLP as its new independent registered public accounting firm, following disclosures of material weaknesses in internal controls over financial reporting.

Greenwich LifeSciences successfully held its annual meeting, electing all director nominees and approving the appointment of its accounting firm and an increase in shares for its equity incentive plan.

Greenwich LifeSciences has entered into a securities purchase agreement with its CEO, Snehal Patel, for a private placement of 174,825 shares at $14.30 per share, raising approximately $2.5 million.

Greenwich LifeSciences has dismissed MaloneBailey LLP and appointed RBSM LLP as its new independent registered public accounting firm, effective February 15, 2024.

Greenwich LifeSciences has provided an update on its Phase III clinical trial, Flamingo-01, for its breast cancer immunotherapy, GLSI-100, including expansion of the trial to include more patients and sites.

Greenwich LifeSciences reported increased net losses and cash burn in Q3 2025, driven by higher R&D and administrative costs, while continuing its Phase III breast cancer immunotherapy trial.

Greenwich LifeSciences reported a significantly wider net loss in Q2 2025, driven by increased R&D and administrative expenses, while also disclosing substantial doubt about its ability to continue as a going concern.

Greenwich LifeSciences reports a net loss for Q1 2025, driven by increased research and development and general and administrative expenses, while continuing to advance its Phase III clinical trial and utilize at-the-market (ATM) offerings for financing.

Greenwich LifeSciences reported its Q3 2024 financial results, highlighting increased research and development expenses and a net loss, while also detailing recent equity sales and a new ATM agreement.

Greenwich LifeSciences' Q2 2024 report reveals a significant increase in research and development expenses as the company expands its Phase III clinical trial for a breast cancer immunotherapy.

Greenwich LifeSciences reported a net loss of $2.47 million for the first quarter of 2024, driven by increased research and development expenses.

Greenwich LifeSciences reports 2025 financial results, highlighting progress in its Phase III Flamingo-01 clinical trial for breast cancer immunotherapy.

Greenwich LifeSciences focuses on its Phase III clinical trial, Flamingo-01, evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, while reporting a net loss of $15.8 million for 2024.

Greenwich LifeSciences' annual report details progress on its Phase III breast cancer immunotherapy trial and its financial position.

Snehal Patel, CEO and CFO, a Director and 10% owner of Greenwich LifeSciences, Inc., purchased 2,200 shares of common stock on July 28, 2026.

Snehal Patel, CEO and CFO, a Director and 10% owner of Greenwich LifeSciences, Inc., purchased 1,500 shares of common stock on July 27, 2026 for $13.62 per share.

Snehal Patel, CEO and CFO, a Director and 10% owner of Greenwich LifeSciences, Inc., purchased 3,600 shares of common stock on July 23, 2026.

Greenwich LifeSciences CEO and CFO Snehal Patel purchased 1,800 shares of common stock, signaling insider confidence.

Greenwich LifeSciences CEO and CFO Snehal Patel purchased 2,900 shares of common stock at $27.54 per share, increasing beneficial ownership to over 5.6 million shares.

Greenwich LifeSciences' CEO and CFO, Snehal Patel, acquired 4,300 shares of common stock at $21.36 per share, increasing beneficial ownership to 5,599,402 shares.

Greenwich LifeSciences, Inc. has filed a Definitive Proxy Statement (SCHEDULE 14A) with the U.S. Securities and Exchange Commission.

Greenwich LifeSciences, Inc. announced its 2025 Annual Meeting of Stockholders to elect directors and ratify its independent accounting firm, alongside detailed executive compensation and corporate governance updates.

Greenwich LifeSciences, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Greenwich LifeSciences is holding its annual meeting to elect directors, ratify its auditor, and increase the shares available under its equity incentive plan.